Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
|Articles|April 1, 1999
The American Journal of Managed Care
- April 1999
- Volume 5
- Issue 4
Celecoxib: A COX-2 Inhibitor
Advertisement
Articles in this issue
over 27 years ago
Medicaid Recipients' Experiences Under Mandatory Managed Careover 27 years ago
Why Primary Care Physicians Join HMOsover 27 years ago
Discontinuation Rates of Cholesterol-Lowering Medicationsover 27 years ago
Is Prior Authorization of Topical Tretinoin for Acne Cost Effective?over 27 years ago
Disease Management of Congestive Heart FailureAdvertisement
Related to this article
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
Medicare's cell and gene therapy payment gap remains, with hospitals absorbing costs as insurers limit coverage.
Congress's Mental Health TALK SAFE Act could expand telepsychiatry access by establishing permanent telehealth prescribing and licensing rules.
CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.
Nonadherence to semaglutide for obesity worsened once out-of-pocket costs passed roughly $75 per 30-day supply among commercially insured adults.
Advertisement
Advertisement
Trending on AJMC
1
Lung Cancer Progress Drives Down US Cancer Death Rates
2
Panel Confronts the Practical Barriers to Bringing Bispecifics Into Community Myeloma Care
3
All 50 States Apply for CMS's GENEROUS Model, With $64.3B in Savings Projected
4
Contributor: Congress Can Bring Mental Health Care to the 21st Century
5